Albion News

Orchard Therapeutics
  - Agreement strengthens Orchard’s position as a global leader in gene therapy for rare diseases - GSK takes 19.9% equity stake in Orchard and seat on board   GSK and Orchard Therapeutics today announced a strategic agreement, under which GSK will transfer its portfolio of approved and investigational rare disease gene therapies to Orchard, securing the continued development of the programmes and access for patients. This acquisition strengthens Orchard’s position as a global leader in gene therapy for rare diseases. GSK will continue to invest in the development of its platform capabilities... read more
Summary
We are pleased to report that in aggregate £32 million was raised being the full amount targeted by the five participating Albion VCTs.  The Albion VCTs Prospectus Top Up Offers 2017/2018 are now all closed.  We have been delighted by the strong support from new and existing shareholders and their advsers.  Unfulfilled application forms will be returned to the applicant and we will notify their adviser.    For further information please contact us directly on 020 7601 1850.  read more
Peter Evans of the Sunday Times has featured UCL Technology Fund in an article about the need to support Britian's academics to commercialise on their ideas. He discussed how the work of the UCL Technology Fund is vital to stop the loss of 'great British ideas' to foreign companies.  Read the full article here (subscription necessary)  read more
Securities Note
We have closed our 2017/2018 VCT top up offers after successfully raising the £32m amount targeted. The offers, which launched on 6 September 2017, are fully subscribed across the five Albion VCTs participating in the fundraising. We will now focus on investing the money raised in technology-driven, high growth companies, with a particular emphasis on its sector specialisms in digital healthcare, automation, digital security and data analytics. Albion has expanded its presence in the technology sector significantly in recent years, with notable investments including Black Swan Data (... read more
Albion has added three new recruits to its technology team as part of its strategic expansion in the sector. Catriona McDonald and Nadine Torbey have joined the firm to help with tech investments from Albion’s VCT portfolios. Tanel Ozdemir has also joined the investment team at Albion Capital as an analyst on the UCL Technology Fund. The hires support the evolution of Albion’s investment strategy towards a greater focus on growth and innovation, and will enable it to seek more opportunities in its specialisms, including data analytics, cybersecurity, digital health, automation and martech.... read more
The UCL Technology Fund has invested in MediaGamma, the predictive analytics software company, as part of a £2m round in partnership with ParkWalk Advisors and the London Co-Investment Fund (LCIF). MediaGamma has developed a world leading enterprise-grade reinforcement machine learning (self-learning) platform, delivering decisions in under five milliseconds. It has proven its technology in programmatic advertising, building and training more accurate user-profiling and bidding algorithms that vastly reduce customer acquisition costs for their clients. The investment will enable MediaGamma to... read more
Mirada Medical
Optellum (Oxford, UK), a high-tech startup in lung cancer and machine learning and Mirada Medical, an established leader in scientifically advanced quantitative imaging software, are announcing a partnership to accelerate the deployment of deep learning technology to market.  This unique collaboration combines the deep technology and clinical expertise of Optellum with the software platforms and rapid development know-how of Mirada.  They have partnered to address a huge and growing problem in lung cancer diagnosis: the management of patients with indeterminate pulmonary nodules. Early... read more
The UCL Technology Fund has invested in Anon AI, the data anonymisation software developer, as part of a £340,000 pre-seed round in partnership with the London Co-InvestmentFund (LCIF), AI Seed and Ascension Ventures.  Anon AI is developing software to automate data anonymisation and help developers and data scientists share data securely. The protection of personal data is a big concern for companies and the pressure to maintain data security will intensify when the General Data Protection Regulation (GDPR) comes into force in May 2018. The investment will enable them to enhance their ... read more
Process Systems Enterprise Inc. (PSE), the Advanced Process Modeling (APM) company, today announced it signed a corporate agreement making its industry leading gPROMS equation-oriented modeling technology accessible throughout ExxonMobil. The agreement also provides for co-development of advanced automation and control applications as part of PSE’s gPROMS Operational Excellence Solutions. The new agreement complements ExxonMobil's long-standing relationship with PSE for detailed engineering design and simulation tools as well as expert consulting services. "We are delighted that ExxonMobil... read more
Orchard Therapeutics
Orchard Therapeutics, a biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, today announced the completion of an oversubscribed $110 million (£85 million) Series B financing.   Baillie Gifford and ORI Capital co-led the financing with significant new investments from Temasek and Cowen Healthcare Investments, alongside Juda Capital, Pavilion Capital, RTW Investments, Agent Capital, 4BIO Capital and existing investors F-Prime Capital and UCL Technology Fund. In conjunction with the financing, Simone Song, senior partner at... read more

Pages